Author:
Abrahamyan Lusine, ,Willan Andrew R.,Beyene Joseph,Mclimont Marjorie,Blanchette Victor,Feldman Brian M.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Institute of Medicine. Rare disease and orphan products: Accelerating research and development. Washington, DC: The National Academies Press; 2010.
2. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36–42.
3. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98:829–836.
4. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331:1016–1019.
5. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195–209.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献